Mark Beer studied at the Miami University located in Ohio graduating with a Bachelor of Science. Today, the individual is a renowned entrepreneur and philanthropist. After completing school, Beer specialized working in diagnostic, pharmaceutical, device, and biotechnology where he worked for over 25 years. During the 25 years, the individual garnered much experience in operation to thorough his career. In 2016, Beer established Renovia Inc. Shortly after starting up the business, the group underwent through the series A funding project. Among many other convergences of technology and medicine, Renovia is the most favorable and recent achievement of Mark Beer. These numerous achievements and the positions Beer held made him suitable to stand as the leader of Renovia.
The $42-million series B funding completed showed great development not just for Renovia but for Mark Beer and the entire Ohio community. Beer showed his leadership skills when he became the chief executive officer of ViaCell. The institution dealt with the development and preservation of the umbilical-cord stem cells. ViaCell later got acquired by the Perkin Elmer who had much experience in the industry. ViaCell opened doors to the public in 2005. Before getting its new possession, the organization had more than 300 employees. Mark Beer worked himself up through various leadership positions. Other posts Beer occupied include the executive vice president of global marketing. All these posts help Beer to develop much experience in diagnostic and pharmaceutical sections. The positions Beer held did not just develop his career in medicine but also gave him a chance to learn what the clients need. Therefore, the patients at Renovia have the right team of leadership in position.
Through the leadership of Mark Beer, Renovia established a product known as Leva. The commodity has a design to help women regain the health of the pelvic floor. The problem of the pelvic floor is spreading at a higher rate in the entire world. Other than Leva, the Renovia and Mark Beer are working tirelessly to invent new products to the market to fight the disease. The institution uses the Leva pelvic digital health system for women to have a quick recovery through exercise. The group uses this training product for the women to ensure that they benefit from the activities by doing them in the right manner. Other body issues appear as a result of the poor pelvic floor health and straightening. When the pelvic floor muscles are weak, you get pelvic floor disorder.
Renovia used some of its resources and funds to open up new clinical trials that began this year. The clinics will determine the effect of Leva on women who use the product when exercising as compared to those who do not use. The institution expected a turnout of over 225 women. Learn more: https://ideamensch.com/marc-beer/
Renovia’s CEO Marc Beer Raises Over $40 Million in Funding and Debt Venture
Marc Beer, the CEO of Renovia has 25 plus years of expertise in the biotechnology, diagnostics, and pharmaceutical industries. Gazette reported the beginning of October 2018 that he raised $32 million in funds and $10 million in venture debt for his new start-up company. He started the company with Ramon Iglesias and Yolanda Lorie as a medical technology entity, in 2016. Their mission is to develop diagnostic and treatment products for women diagnosed with pelvic disorders. Throughout his career, he’s started successful businesses and serves on the board of directors for companies and educational institutions.
When Beer started Renovia, he received his first round of funding from healthcare investment group, Longwood Fund. With the help of Perceptive Advisers and Ascension Ventures, he raised the second round of funding to support four of their products. In April of this year, the FDA approved a new product, Leva produced by the company. Marc told Gazette he now can improve the diagnosis and treatment for women diagnosed with the pelvic disorder. He plans to lead the development with the combination of proprietary technologies and a digital health forum.
The technologies and forum will provide educational and informative information that produces treatment options to customers. The goal is to increase understanding of the disorder that will eventually lead to reducing health care costs long term. Marc Beer explains that they designed treatments to restore pelvic health using various solutions to strengthen the muscles. He says Renovia plans to create a new generation of Leva for patients suffering from urinary contingency disorders. Pelvic floor disorder effects 250 million women and is treatable with the proper products.
Before co-finding Renovia, Marc Beer found ViaCell, a biotechnology company specializing in the development, preservation, and collection of blood stem cells. He started the business in 2000 and experienced rapid growth within seven years. By 2005, ViaCell became a public traded enterprise with 300 workers. Beer held positions with Global Marketing, Genzyme, Abbott Laboratories, Erytech Pharma, Good Start Genetics, Minerva Neurosciences, and Commonwealth of Massachusetts. His executive titles include vice president, board member director, chief executive officer, and chairman.
Marc is a Miami University graduate earning a BA in Business Science, in 1987. He has over 25 years of experience in development and commercialization in the devices, diagnostics, pharmaceutical, and biotechnology fields. While serving on the board of directors for a cancer foundation, he helped many cancer patients and their families during difficult times. Beer serves as a member of the Miami University Business Advisory Council. He served on the Graduate Studies Research and Advisory Council and the Research and Commercialization Advisory Committee at Notre Dame. Learn more: https://www1.salary.com/Marc-Beer-Salary-Bonus-Stock-Options-for-AEGERION-PHARMACEUTICALS-INC.html
Renovia Inc. has recently closed on $32 million of Series B funding to go ahead with new products treat pelvic floor disorders. The company, which was co-founded by Marc Beer in 2016, also received $10 million in venture capital as well.
The funds will be used to develop four new products addressing pelvic floor ailments, though details were not released by the company. Bizjournals.com said they will address diagnostic and therapeutic improvements that address ailments that may include urinary incontinence. Marc Beer said in a statement the company aims to improve its sensor technology to give healthcare providers the tools to incorporate better data in their treatment strategies. Beer went on to say that these improvements will “eventually” bring down healthcare costs.
The Series B included money from the Longwood Fund, which was an early investor in the Beer’s co-founded company. The Series B process was led by Perspective Advisors, based out of New York, and Missouri-based Ascension Ventures. Renovia Inc. developed the drug Leva, which was approved by the FDA back in April. The Series B funding will partly be used will be used to create a new generation of Leva, it was said in the bizjournals.com article.
Marc Beers joined two others, Ramon Iglesias and Yolanda Lorie, to create Renovia in August 2016 and was instrumental in securing the Series A funding used to develop Leva. The Longwood fund was one of those initial investors. Marc Beers co-founded Renovia Inc. after a long tenure in the medical field, has commercialized a number of products in the areas of biotechnology, pharmaceuticals, devices and diagnostics.
Among other companies he started was ViaCell, a biotechnology company that focuses on the collection, preservation, and development of umbilical cord stem cells. He led the company from inception to its growth to 300 employees to ts eventual sale to PerkinElmer in 2007. Prior to that, Marc Beers was a member of the board of directors of Erytech Pharma and held positions with Genzyme where he served most recently as the vice president of global marketing where he was instrumental in the launch of drugs addressing rare diseases across the globe. Learn more: https://renoviainc.com/leadership/
Marc Beer has extensive experience and expertise in commercialization and development in pharmaceuticals, diagnostics, devices, and biotechnology. Marc Beer cofounded Revonia alongside Yolanda Lorie, MD, and Ramon Iglesias in August 2016. The company has successfully achieved a Series A Financing with top healthcare business capital funds since its creation in 2016.
Marc Beer was appointed the Founding Chief Executive Officer of ViaCell in April 2010. ViaCell is a biotechnology firm that focuses on the activities that are involved in the collection, preservation, and development of blood stem cells of the human umbilical cord. Marc Beer led the management of ViaCell for over seven years. He helped the company to grow from its inception to become one of the rapidly growing firms with the intense commercialization of its products and services.
Marc Beer’s leadership and management of ViaCell helped it to go public in 2005, developed to offer over 300 job opportunities, and later purchased by PerkinElmer in the year 2007. Marc Beer dedicated his time and skills to ensure that he used his position as the CEO of the ViaCell to propel it from its humble beginning to attaining international standards.
Marc Beer was also a Board member of the Board of Directors of Erytech Pharma. Erytech Pharma is a publicly traded company that provides pharmaceutical products and services. He was key personnel in the board as he represented the firm in a variety of development forums. Marc Beer also held a variety of positions in Genzyme. One of the most recent post that Mr. Marc held within Genzyme was that of the Vice President of Global Marketing. Under this rank, Mr. Marc Beer was tasked with the responsibilities of the commercial launching of various products that addressed several rare diseases that affected populations around the globe.
Before joining Genzyme, Marc spent years serving Abbott Laboratories where he held various roles in sales and marketing in the diagnostic and pharmaceutical divisions. Marc was also in the Mass Life Science Board of the Massachusetts Commonwealth. He worked in the Emerging Companies Section Governing Board of the Biotechnology Industry Organization.
Marc Beer was among the founders and Founding Chairman of the Board of directors of Good Start Genetics, Inc. He was also the Chairman of the compensation committee of the organization. The Good Start Genetics, Inc. was purchased by InVatae Company just recently. Marc Beer also played some vital roles in the foundation of Minerva Neurosciences, Inc. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer